A collagen matrix at immediate implants kept the mucosa thicker at 12 months

Source study: Immediate Implants With or Without a Volume Stable Collagen Matrix: A Randomized Clinical Trial. — Clinical oral implants research

In brief

  • With the collagen matrix, soft tissue thickness was significantly greater at every follow-up (38 patients, anterior esthetic zone).
  • The mucosal level stayed stable with the matrix; the control group showed significant recession and volumetric shrinkage.
  • Marginal bone level did not change significantly in either group.
  • Follow-up is limited to 12 months.

An implant placed at the time of extraction in the anterior esthetic zone sits in soft tissue that can thin and recede during the following months. This randomized clinical trial asked whether a volume-stable collagen matrix (VCMX), placed at the same surgery, changes soft tissue thickness around immediate implants compared with no soft tissue augmentation.

Forty patients received immediate implants in the anterior esthetic zone, with simultaneous VCMX in the test group and without it in the control group; 38 completed the study. Assessments were made before surgery, immediately after surgery, and at 6 and 12 months. The primary outcome was soft tissue thickness. Secondary outcomes were mucosal level, marginal bone level (MBL), esthetic and patient-reported outcomes, and volumetric change.

Soft tissue thickness was significantly greater in the test group at every follow-up. At 12 months, thickness in the test group had increased by 1.85 mm at 3 mm from the gingival margin, a significant change. At 6 mm the increase was 1.29 mm and did not reach significance. In the control group, thickness decreased by 0.18 mm at 3 mm and by 0.36 mm at 6 mm; neither change was significant.

The mucosal level remained stable with the matrix, while the control group showed significant recession. Volumetric analysis told the same story: no significant change over time in the test group, significant shrinkage in the control group. Selected esthetic and patient-reported outcomes favored the test group. MBL did not change significantly in either group, so the benefit in this trial concerns the soft tissues and not the bone.

For the clinician placing immediate implants in the esthetic zone, the trial supports the matrix as an option when the goal is to preserve soft tissue thickness and mucosal level, with one year of follow-up in a sample of 38 patients. The authors' own conclusion is cautious: VCMX may improve soft tissue stability. The abstract does not compare the matrix with a connective tissue graft, so the data say nothing about which of the two performs better, and longer follow-up is needed to know whether the difference lasts.

Why it matters in practice

In this trial, a matrix placed at the same surgery was associated with thicker and more stable soft tissue around immediate implants in the esthetic zone. The data do not show whether it can stand in for a connective tissue graft.

This summary is automatically generated from the original abstract and curated by Dr. Ernesto Bruschi. Always refer to the original publication for clinical decisions.